immunoprecipitation (IP): 10-20 μg using a nuclear extract of HeLa cells indirect immunofluorescence: 4-8 μg/mL using human HeLa cells microarray: suitable western blot: 0.5-1 μg/mL using nuclear extract of HeLa cells
The SUMO-1 (small ubiquitin-like modifier 1) gene is mapped to human chromosome 2q33.1 and is highly conserved. The protein structure includes an α-helix core surrounded by four-stranded β-sheets.
면역원
synthetic peptide corresponding to amino acid 1-16 located at the N-terminus of human SUMO-1, conjugated to KLH. The sequence is identical in many species including mouse, rat, dog, bovine, and highly conserved (single amino acid substitution) in chicken and Xenopus SUMO-1. It is not found in human SUMO-2 and SUMO-3.
애플리케이션
Anti-SUMO-1 antibody produced in rabbit has been used in immunoblotting assay.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Western Blotting (1 paper)
생화학적/생리학적 작용
SUMO (small ubiquitin-like modifier) proteins are associated with a number of cellular processes. SUMOylation mediated by SUMO1 is involved in nuclear transport mechanism, apoptosis, regulation of cyclin-dependent kinase 6 and protein stability. SUMO1 regulates tumor suppressor p53 protein, a transcription factor that is termed as the “guardian of the genome” plays a key role in the cell cycle events. Unlike ubiquitination which directs proteins for degradation, SUMOylation aims to alter the stability, localization and the function of the target protein.
물리적 형태
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
면책조항
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
We previously reported that destruction of the small ubiquitin-like modifier (SUMO) modification site in the axonal collapsin response mediator protein 2 (CRMP2) was sufficient to selectively decrease trafficking of the voltage-gated sodium channel NaV1.7 and reverse neuropathic pain. Here, we
Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.
Ke J, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 37(9), 12203-12211 (2016)
SUMOylation represses the transcriptional activity of the Unfolded Protein Response transducer ATF6.
Hou X, et al.
Biochemical and Biophysical Research Communications, 494(3), 446-451 (2017)
